PDF
Kurs
+3,86%
Kurs
+3,86%
Open
1,30
High
1,60
Low
1,29
Close
1,34
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
0,58 MNOK
Likviditet
0,58 MNOK
Rel. mcap
1,06%
Antal aktier
428 268
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2025-08-28 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-06-05 | N/A | Årsstämma |
| 2025-04-10 | 00:00 | Bokslutskommuniké 2024 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-19 | - | Årsstämma |
| 2024-06-06 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2024-04-25 | - | Bokslutskommuniké 2023 |
| 2023-10-04 | - | Split CRNA 30:1 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-22 | - | Årsstämma |
| 2023-04-21 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2023-03-09 | - | Extra Bolagsstämma 2023 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-11-03 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-18 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-20 | - | Årsstämma |
| 2022-04-07 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-25 | - | Extra Bolagsstämma 2021 |
| 2021-11-04 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-18 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | - | Kvartalsrapport 2021-Q1 |
| 2021-03-18 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2021-03-17 | - | Årsstämma |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-07 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-30 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2020-04-29 | - | Årsstämma |
| 2020-03-11 | - | Bokslutskommuniké 2019 |
| 2019-11-07 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-09 | - | Kvartalsrapport 2019-Q1 |
| 2019-04-10 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2019-04-09 | - | Årsstämma |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-01 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-23 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-03 | - | Kvartalsrapport 2018-Q1 |
| 2018-04-12 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2018-04-11 | - | Årsstämma |
| 2018-02-15 | - | Bokslutskommuniké 2017 |
| 2017-11-16 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-25 | - | Kvartalsrapport 2017-Q1 |
| 2017-04-05 | - | Årsstämma |
| 2017-02-16 | - | Bokslutskommuniké 2016 |
| 2016-11-17 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-25 | - | Kvartalsrapport 2016-Q2 |
| 2016-05-12 | - | Kvartalsrapport 2016-Q1 |
| 2016-04-14 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2016-04-13 | - | Årsstämma |
| 2015-06-23 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
| 2015-06-22 | - | Årsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2024-08-29 07:00:00
Oslo, Norway, 29 August 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA gene therapies, today announces its first half-year 2024 results.
Circio's management will present the results in a live-streamed webcast at 10:00 am CEST to investors, analysts and the press. Click here for access to the live webcast (http://teams.microsoft.com/l/meetup-join/19%3ameeting_N2U2Njg5OTYtYjZjMC00MDBlLThlMjUtZjg4MTQwOTYzMDUy%40thread.v2/0?context=%7b%22Tid%22%3a%2266b0661a-3ec3-48a8-a966-5b0cce82b3fe%22%2c%22Oid%22%3a%223f5f84b0-5521-4c04-bd8a-e185546abe04%22%7d)
Questions can be submitted by email in advance (to: lubor.gaal@circio.com)and during the presentation.
Reporting material attached to this press release:- Circio first-half year report 2024
- Circio 1H24 webcast presentation
The report and presentation are also available at www.circio.com
***
First half-year 2024 highlights
Corporate- In January, Business Finland approved Circio's application for a waiver of three R&D loans totaling NOK 71.3 million
- In May, launched a financing transaction securing cash runway for 12 months through a rights issue and parallel commitment from Atlas Capital Markets
- Cash burn of NOK 19 million, representing a 68% reduction versus 1H23
- In April, announced technical in vivo proof-of-concept for its proprietary circVec circular RNA platform with >4-month expression durability
- In May, presented two circVec posters at the American Society of Gene & Cell Therapy (ASGCT) 2024 annual meeting in Baltimore, USA
- In June, announced a new generation circVec 2.2, achieving 2-4-fold higher expression than v2.1 and up to 15x improvement over mRNA expression
- In February, announced that the first patient was dosed in the Georgetown University Phase 2 study, testing TG01 in a triple combination in collaboration with Janssen and BMS
- In March, the Chinese National Medical Products Administration (NMPA) approved the investigational new drug (IND) application of TG01
***
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com